[go: up one dir, main page]

RU2007124538A - PHARMACEUTICAL COMPOSITION FOR GENE THERAPY OF DISEASES REQUIRING STIMULATION OF REGENERATORY PROCESSES, INCLUDING DAMAGE TO HUMAN TISSUES OF VARIOUS ETHIOLOGY PERIODIC HYDROGEN - Google Patents

PHARMACEUTICAL COMPOSITION FOR GENE THERAPY OF DISEASES REQUIRING STIMULATION OF REGENERATORY PROCESSES, INCLUDING DAMAGE TO HUMAN TISSUES OF VARIOUS ETHIOLOGY PERIODIC HYDROGEN Download PDF

Info

Publication number
RU2007124538A
RU2007124538A RU2007124538/15A RU2007124538A RU2007124538A RU 2007124538 A RU2007124538 A RU 2007124538A RU 2007124538/15 A RU2007124538/15 A RU 2007124538/15A RU 2007124538 A RU2007124538 A RU 2007124538A RU 2007124538 A RU2007124538 A RU 2007124538A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
pgsyntigf
fgsintifr
insulin
gene
Prior art date
Application number
RU2007124538/15A
Other languages
Russian (ru)
Other versions
RU2372941C2 (en
Inventor
Игорь Альбертович Иванов (RU)
Игорь Альбертович Иванов
Original Assignee
Духовлинов Иль Владимирович (RU)
Духовлинов Илья Владимирович
Игорь Альбертович Иванов (RU)
Игорь Альбертович Иванов
Общество с ограниченной ответственностью "Фарма Ген" (RU)
Общество С Ограниченной Ответственностью "Фарма Ген"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Духовлинов Иль Владимирович (RU), Духовлинов Илья Владимирович, Игорь Альбертович Иванов (RU), Игорь Альбертович Иванов, Общество с ограниченной ответственностью "Фарма Ген" (RU), Общество С Ограниченной Ответственностью "Фарма Ген" filed Critical Духовлинов Иль Владимирович (RU)
Priority to RU2007124538/15A priority Critical patent/RU2372941C2/en
Publication of RU2007124538A publication Critical patent/RU2007124538A/en
Application granted granted Critical
Publication of RU2372941C2 publication Critical patent/RU2372941C2/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (6)

1. Фармацевтическая композиция или препарат для генной терапии, включающие синтетический модифицированный ген инсулиноподобного фактора роста человека 1 (ФГсинтИФР-1, PGsyntIGF-1) в составе любого вектора.1. A pharmaceutical composition or preparation for gene therapy, comprising a synthetic modified gene of insulin-like human growth factor 1 (FGSintIFR-1, PGsyntIGF-1) in any vector. 2. Рекомбинантная плазмидная ДНК (pCIGF-lsynt), содержащая синтетический модифицированный ген инсулиноподобного фактора роста человека 1 (ФГсинтИФР-1, PGsyntIGF-1).2. Recombinant plasmid DNA (pCIGF-lsynt) containing a synthetic modified gene of insulin-like human growth factor 1 (FGSintIFR-1, PGsyntIGF-1). 3. Эукариотический продуцент белка ИФР-1, содержащий синтетический модифицированный ген инсулиноподобного фактора роста человека 1 (ФГсинтИФР-1, PGsyntIGF-1).3. The eukaryotic producer of the IGF-1 protein, containing a synthetic modified gene of insulin-like human growth factor 1 (FGSintIFR-1, PGsyntIGF-1). 4. Нуклеотидная последовательность синтетического гена инсулиноподобного фактора роста человека 1 (ФГсинтИФР-1, PGsyntIGF-1), за счет которой достигается увеличенная стабильность мРНК в клетках млекопитающих, что ведет к увеличению синтеза кодируемого белка до 4-100 и более раз по сравнению с использованием в аналогичных условиях нативного природного гена.4. The nucleotide sequence of the synthetic gene of insulin-like human growth factor 1 (FGSintIFR-1, PGsyntIGF-1), due to which increased stability of mRNA in mammalian cells is achieved, which leads to an increase in the synthesis of the encoded protein up to 4-100 or more times compared to using in similar conditions to the native natural gene. 5. Применение фармацевтической композиции или препарата по п.1 для лечения заболеваний путем стимуляции регенерации широкого спектра тканей человека, включающих в себя мышечную, костную, все виды соединительной ткани, хрящевую, эпидермальную, нервную ткань.5. The use of the pharmaceutical composition or preparation according to claim 1 for the treatment of diseases by stimulating the regeneration of a wide range of human tissues, including muscle, bone, all types of connective tissue, cartilage, epidermal, nervous tissue. 6. Применение фармацевтической композиции или препарата по п.1 для лечения различных заболеваний, включая механические, химические, термические, местные радиационные и электрические, а также послеоперационные травмы и т.п. 6. The use of the pharmaceutical composition or preparation according to claim 1 for the treatment of various diseases, including mechanical, chemical, thermal, local radiation and electrical, as well as postoperative injuries, etc.
RU2007124538/15A 2007-07-02 2007-07-02 Pharmaceutical composition for genetic therapy of diseases requiring stimulation of regenerative processes, including human tissue damages of various aetiologies, based on synthetic modified gene of insulin-like human growth factor type one (ifr-1, igf-1) RU2372941C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2007124538/15A RU2372941C2 (en) 2007-07-02 2007-07-02 Pharmaceutical composition for genetic therapy of diseases requiring stimulation of regenerative processes, including human tissue damages of various aetiologies, based on synthetic modified gene of insulin-like human growth factor type one (ifr-1, igf-1)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2007124538/15A RU2372941C2 (en) 2007-07-02 2007-07-02 Pharmaceutical composition for genetic therapy of diseases requiring stimulation of regenerative processes, including human tissue damages of various aetiologies, based on synthetic modified gene of insulin-like human growth factor type one (ifr-1, igf-1)

Publications (2)

Publication Number Publication Date
RU2007124538A true RU2007124538A (en) 2009-01-10
RU2372941C2 RU2372941C2 (en) 2009-11-20

Family

ID=40373750

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007124538/15A RU2372941C2 (en) 2007-07-02 2007-07-02 Pharmaceutical composition for genetic therapy of diseases requiring stimulation of regenerative processes, including human tissue damages of various aetiologies, based on synthetic modified gene of insulin-like human growth factor type one (ifr-1, igf-1)

Country Status (1)

Country Link
RU (1) RU2372941C2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694049B2 (en) 2011-08-11 2017-07-04 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The Unitversity Of Nevada, Reno Methods for treating muscular dystrophy
KR102354389B1 (en) * 2013-08-21 2022-01-20 큐어백 아게 Method for increasing expression of RNA-encoded proteins
WO2020016655A2 (en) 2018-07-17 2020-01-23 Helixmith Co., Ltd. Treatment of neuropathy with dna constructs expressing igf-1 isoforms
RU2711111C1 (en) * 2018-09-05 2020-01-15 Илья Владимирович Духовлинов Hybrid protein igf-1-long for treating stroke, nucleic acid, vector, cell, pharmaceutical composition, method of treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987001038A1 (en) * 1985-08-22 1987-02-26 Commonwealth Scientific And Industrial Research Or Peptide analogues of mammalian insulin-like growth factor-1
US4963665A (en) * 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells

Also Published As

Publication number Publication date
RU2372941C2 (en) 2009-11-20

Similar Documents

Publication Publication Date Title
RU2649069C2 (en) Novel method for treating spinal cord injury using hmgb1 fragment
CN111944057A (en) Recombinant human collagen peptide and application thereof
ZA200800533B (en) Glycosylated IL-7, preparation and uses
BRPI0416683A (en) human 21 fibroblast growth factor mutant (fgf-21), or a biologically active peptide thereof, polynucleotide, expression vector, host cell, process for producing a polypeptide, pharmaceutical composition, method for treating a patient, and, use da muteìna fgf-21
ATE365045T1 (en) PRODUCTION OF SOFT AND BONE TISSUE USING PRECURSOR CELLS FROM MUSCLE, AS WELL AS ASSOCIATED COMPOSITIONS AND FORMS OF TREATMENT
BR0007663A (en) Acyl derivatives for use in the treatment of diseases related to vla-4
BRPI0411817A (en) apparatus and method for bioelectric stimulation, healing acceleration, pain relief or pathogen devitalization
JP2012518420A5 (en)
RU2008115678A (en) PEPTIDS ABLE TO CONTACT TRANSFORMING BETA 1 GROWTH FACTOR (TGF-BETA 1)
CA2596597A1 (en) Method for stimulation collagen synthesis and/or kgf expression
BRPI0415563A (en) method for treating parkinson's disease, use of a viral vector, viral expression vector, pharmaceutical composition, isolated host cell, packaging cell line, chimeric non-human mammal, implantable cell culture device, biocompatibly capsule, method for treatment of a nervous system disease, mammalian cell, and, method for producing neurturin or a functional equivalent thereof
CN114316029B (en) Transdermal absorptive peptide and recombinant collagen constructed by repetition of the same
RU2007124538A (en) PHARMACEUTICAL COMPOSITION FOR GENE THERAPY OF DISEASES REQUIRING STIMULATION OF REGENERATORY PROCESSES, INCLUDING DAMAGE TO HUMAN TISSUES OF VARIOUS ETHIOLOGY PERIODIC HYDROGEN
AR037038A1 (en) A COMPOSITION AND METHOD TO ALTER THE MAGRA BODY MASS AND THE OSEAS PROPERTIES IN A SUBJECT
CN117903293B (en) A triple helical collagen with thermal stability and promoting self-collagen production, and preparation method and use thereof
CN114316030A (en) I-type recombinant collagen with high transdermal absorbability and application thereof
AU2017249629B2 (en) Method for the treatment or prevention of osteoarthritis.
CN119930801B (en) High-thermal-stability bionic collagen, cosmetics, medicines, tissue engineering materials or medical instruments, and preparation method and application thereof
ATE554160T1 (en) BONE BUILDING USING PRECURSOR COMPOSITIONS FROM MUSCLES AND TREATMENTS THEREWITH
WO2007056433A3 (en) Methods of treating tissue defects
CN1807460A (en) Recombinant fusion protein of fibroin and RGD, and its biological synthesis method
CN102485888A (en) Effect of pulse electromagnetic field on promotion of in vitro osteogenesis and differentiation of human umbilical cord mesenchymal stem cells
NORTON Implications of bioelectric growth control in orthodontics and dentistry
US20120065574A1 (en) Isoform nell-1 peptide
Kim et al. An implantable electrical bioreactor for enhancement of cell viability

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20091009

NF4A Reinstatement of patent

Effective date: 20110227

MM4A The patent is invalid due to non-payment of fees

Effective date: 20120703

NF4A Reinstatement of patent

Effective date: 20140527

HE4A Notice of change of address of a patent owner

Effective date: 20190702